Business Context and Reporting Period
Company: NeOnc Technologies Holdings, Inc. (NTHI)
Filing Type: Form 8-K (Current Report)
Date of Report: March 12, 2026
Reporting Period: Event-based (Appointment of Officer and Entry into Agreement)
Business Overview: The Company is a clinical-stage biotechnology firm advancing its platform and expanding global operations. It is registered on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and personnel changes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes
- Executive Appointment: The Board appointed David Choi as Chief Accounting Officer, effective March 12, 2026.
- Compensation Agreement: Mr. Choi entered into an employment agreement with a base salary of $162,500 per year.
- Equity Grant: Mr. Choi was granted 170,000 restricted shares under the 2023 Equity Incentive Plan.
Guidance, Outlook, and Management Commentary
Management Commentary: Mr. Choi is tasked with overseeing accounting, financial reporting, internal controls, and corporate governance. His focus includes building scalable finance infrastructure and strengthening reporting processes to support the Company's growth as a public company.
Equity Vesting Schedule:
- Immediate Vesting: 53,333 shares vested on March 12, 2026.
- Time-Based Vesting: 58,333 shares vest at the one-year anniversary of employment.
- Performance-Based Vesting: 58,334 shares vest based on specific performance metrics outlined in the individual grant agreement.
Risks and Contingencies: No specific risks or contingencies were disclosed in this filing other than the standard incorporation of the full agreement terms by reference.
Key Facts for Investor Verification
- Verify the specific performance metrics required for the vesting of the 58,334 performance-based restricted shares by reviewing Exhibit 10.2 (Restricted Stock Award Agreement).
- Confirm the total equity dilution impact of the 170,000 share grant relative to the Company's current outstanding share count.
- Review the full Employment Agreement (Exhibit 10.1) for termination provisions, severance terms, and non-compete clauses.
- Monitor future filings for the Company's next periodic report (10-Q or 10-K) to assess financial performance, as this 8-K contains no financial data.